RDP indicated as possible ED and PBT: Conclusions of the Risk Management Option Analysis (RMOA) carried out by the French authorities for ECHA on RDP (Tetraphenyl resorcinol bis(diphenylphosphate) = Tetraphenyl m-phenylene bis (phosphate), EC# 260-830-6) suggest that it may be an endocrine disruptor (ED) and persistent – bioaccumulative – toxic (PBT). Resorcinol, as a metabolite of RDP in the body, is indicated as probably without effects, but TPP (Triphenyl phosphate) generally present as an impurity in RDP may account for some of the observed effects. RDP was added to the ECHA CORAP list (Community Rolling Action Plan) in early 2018 – see pinfa Newsletter n°89
ECHA website – CORAP – RMOA for RDP (March 2018) Risk Management Option Analysis https://echa.europa.eu/pact/-/substance-rev/12936/term